# OnCo record gadopiclenol (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/gadopiclenol/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "gadopiclenol" ;
  schema:name "Gadopiclenol"@en ;
  schema:alternateName "gadopiclenol"@en, "Elucirem"@en, "Vueway"@en, "Elucirem" ;
  schema:description "A newer MRI dye given into a vein, approved in 2022 in the United States and 2023 in Europe, for brain and body scans including the liver, breast, lung and prostate in Europe."@en ;
  schema:url <https://onco.cc/drugs/gadopiclenol/> ;
  schema:dateModified "2026-11-04"^^xsd:date ;
  schema:citation <https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=216986>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=192725e9-e83e-1a36-33f2-abee55792ab3>, <https://www.ema.europa.eu/en/medicines/human/EPAR/elucirem>, <https://www.ema.europa.eu/en/medicines/human/EPAR/vueway>, <https://atcddd.fhi.no/atc_ddd_index/?code=V08CA&showdescription=no> ;
  onco:status "approved" ;
  onco:tag "contrast-agents-gaps-2026-11", "diagnostic" ;
  onco:modality "Gadolinium-based contrast agent for MRI of the brain and body (intravenous)" ;
  onco:approval "US 2022: MRI of lesions with abnormal vascularity in the central nervous system and the body", "EU 2023: Contrast-enhanced MRI of the central nervous system and the liver, kidney, pancreas, breast, lung, prostate and musculoskeletal system" ;
  onco:cancers <https://onco.cc/cancers/glioblastoma/>, <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/prostate/> ;
  onco:technologies <https://onco.cc/technologies/gadolinium-based-contrast-agents/>, <https://onco.cc/technologies/mri/> ;
  onco:companies <https://onco.cc/companies/guerbet/>, <https://onco.cc/companies/bracco/> .